MedAxiom Announces Corporate Partnership with HeartFlow, Inc.

Partner News | Published: Friday, March 1, 2019 6:00 am


MedAxiom is excited to announce its corporate partnership with HeartFlow, Inc., a medical technology company redefining the way heart disease is diagnosed and treated.

“The use of the HeartFlow Analysis to identify opportunities for intervention, or lack thereof, will drastically change an organization’s ability to be competitive in a value-based world,” said Joe Sasson, Ph.D., EVP of MedAxiom Ventures. “We are excited about partnering with HeartFlow to bring the latest technology to our membership to advance patient outcomes through improved diagnosis and management of Coronary Artery Disease.”

Recently named one of the World’s Most Innovative Companies by Fast Company, HeartFlow is uniquely positioned at the intersection of advanced artificial intelligence (AI) capabilities and cardiovascular healthcare. HeartFlow’s flagship product, the HeartFlow FFRCT Analysis, is the first and only non-invasive technology for Coronary Artery Disease (CAD) that offers insight into both the extent of a coronary artery narrowing and whether it is impacting blood flow. By non-invasively providing information to help clinicians identify which patients do and do not need further invasive assessment, the HeartFlow Analysis helps clinicians ensure their patients receive the best possible care, while reducing unnecessary testing and healthcare system costs. 1 To date, clinicians have used the HeartFlow Analysis for more than 30,000 patients to aid in the diagnosis of heart disease.

“The impact of coronary artery disease is enormous, yet the most commonly used testing options for suspected CAD are imperfect, often leading to inaccurate diagnoses or multiple tests. With the HeartFlow Analysis, physicians are able to review highly accurate and actionable information to ensure their patients receive the best possible care,” said John H. Stevens, M.D., president and chief executive officer of HeartFlow. “We look forward to working with MedAxiom to make our innovative approach to help diagnose and treat heart disease available to more physicians and patients.”

The HeartFlow Analysis is a personalized cardiac test for stable symptomatic patients with coronary artery disease (CAD). Starting with a standard coronary CT scan, the HeartFlow Analysis creates a digital, color-coded, personalized 3D model of the patient’s coronary arteries and simulates blood flow. The interactive 3D model is provided via a secure online interface and enables physicians to assess the impact any blockages have on blood flow to the heart. The HeartFlow Analysis offers actionable information to help clinicians determine the optimal course of treatment for their patients.

 

MedAxiom members will have an opportunity to learn more about HeartFlow at the CV Transforum Spring’19 conference, April 3-5, in Amelia Island, FL.

Learn more about HeartFlow at https://www.heartflow.com